ESR1 and breast carcinoma: Co-targeting ERα via SERM or SERD treatment and IRS1 via NT-157 had an additive antiproliferative effect on cells expressing homozygous ERα Y537S, indicating a potential treatment avenue for restoring ET sensitivity to resistant breast cancers expressing ERα Y537S.